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Abstract
Recent studies have suggested that statins, an established drug group in the prevention of cardiovascular mortality, could
delay or prevent breast cancer recurrence but the effect on disease-specific mortality remains unclear. We evaluated risk of
breast cancer death among statin users in a population-based cohort of breast cancer patients. The study cohort included
all newly diagnosed breast cancer patients in Finland during 1995–2003 (31,236 cases), identified from the Finnish Cancer
Registry. Information on statin use before and after the diagnosis was obtained from a national prescription database. We
used the Cox proportional hazards regression method to estimate mortality among statin users with statin use as time-
dependent variable. A total of 4,151 participants had used statins. During the median follow-up of 3.25 years after the
diagnosis (range 0.08–9.0 years) 6,011 participants died, of which 3,619 (60.2%) was due to breast cancer. After adjustment
for age, tumor characteristics, and treatment selection, both post-diagnostic and pre-diagnostic statin use were associated
with lowered risk of breast cancer death (HR 0.46, 95% CI 0.38–0.55 and HR 0.54, 95% CI 0.44–0.67, respectively). The risk
decrease by post-diagnostic statin use was likely affected by healthy adherer bias; that is, the greater likelihood of dying
cancer patients to discontinue statin use as the association was not clearly dose-dependent and observed already at low-
dose/short-term use. The dose- and time-dependence of the survival benefit among pre-diagnostic statin users suggests a
possible causal effect that should be evaluated further in a clinical trial testing statins’ effect on survival in breast cancer
patients.
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Introduction
Breast cancer is the leading cause of cancer death among
women globally. [1] Experimental studies suggest that statins, a
well-established group of cholesterol-lowering drugs, may have
antitumor properties against this common cancer. [2–4].
Statins reduce cholesterol biosynthesis in the liver by inhibiting
3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR),
the rate-limiting enzyme in the mevalonate pathway. In addition
to cholesterol, this pathway produces isoprenoids that are critical
for regulation of cell growth. [5] The pathway is also essential for
tumor promoting effects of oncogene p53. [6] Further, cholesterol
is a critical component of intracellular lipid-rafts, which are crucial
for intracellular signaling. [7] Thus statins’ anticancer effects have
a biologically plausible background.
Despite promising preclinical results, there is no clear associ-
ation between statin use and breast cancer incidence. [8]
However, some recent studies have reported lowered overall
cancer mortality among statin users, [9–13] including one study
that reported decreased breast cancer mortality among pre-
diagnostic statin users, [13] and other studies have suggested that
statin use is associated with improved recurrence-free survival
among breast cancer patients. [14–17] Therefore statins may exert
a greater effect on cancer progression versus initiation.
We studied the association between statin use and breast cancer
mortality among breast cancer patients in a nationwide popula-
tion-based cohort.
Materials and Methods
Data sources
We used the Finnish cancer registry to obtain information on all
breast cancer cases diagnosed in Finland from 1995 to 2003. Due
to mandatory reporting of all cancer diagnoses made in the
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Finnish health care units, the Finnish Cancer Registry has good
national coverage, including over 99% of cancer cases in Finland.
[18] The information on breast cancer cases included the date of
diagnosis, tumor stage (local vs. metastatic, available for 92% of
cases in our cohort), tumor morphology (available for all cases),
initial treatment selection (surgery, radiation therapy, chemother-
apy, hormonal therapy or other) and date and cause of death
(cancer death vs. death due to other causes). Information on tumor
hormone receptor status or screening history was not available.
However, the screening participation rate for breast cancer
screening in Finland has been reported to be up to 90% [19].
Detailed, individual-level information on usage of cholesterol-
lowering drugs between Jan. 1,1995 and Dec. 31, 2003 was
obtained from the national prescription database managed by
Social Insurance Institution of Finland (SII). Cancer cases were
linked to the prescription database using a unique personal
identification number.
SII is a governmental agency providing reimbursements to each
Finnish citizen for the cost of medicines prescribed by a physician
and purchased in outpatient setting. All reimbursed purchases of
drugs approved by the SII (most prescription drugs in clinical use)
are recorded in the database. [20] The prescription database
includes information on date, dosage, package size and number of
packages obtained for each reimbursed purchase.
The cholesterol-lowering drugs in clinical use during the study
period and recorded by the prescription database were statins
(atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin,
rosuvastatin and simvastatin), fibrates (bezafibrate, clofibrate,
fenofibrate and gemfibrozil) and bile-acid binding resins (choles-
tyramin and cholestipol).
Identification of the study cohort
All histologically confirmed invasive breast cancer cases
diagnosed in Finnish health care units from 1995 to 2003 and
recorded in the Finnish Cancer Registry were included in our
Table 1. Baseline population characteristics of all breast cancer cases diagnosed in Finland during 1995–2003.
Non-users of any cholesterol-
lowering drugs Statin usersa Fibrate or resin usersa
n (%) 26,941 (86.2%) 4,151 (13.3%) 313 (1%)
Median age at diagnosis (yrs) 58 64 65
P-value Reference ,0.001 ,0.001
Age-groupb
.= 55 years 15,919 (59.3%) 3,383 (81.5%) 249 (79.6%)
,55 years 10,918 (40.7%) 768 (18.5%) 64 (20.4%)
P-value Reference ,0.001 ,0.001
Deaths; n (% of the subgroup) 5,658 (21.0%) 318 (7.6%) 50 (16.0%)
Breast cancer deaths; n (% of all deaths) 3,434 (60.7%) 166 (52.2%) 27 (54%)
Years of follow-up (median; 95% range) 3.17 (0.08–8.50) 3.83 (0.08–8.67) 3.50 (0.25–8.51)
Stage at diagnosis:
Local; n (%) 22,747 (84.8%) 3,696 (89.0%) 277 (88.5%)
Metastatic; n (%) 1,899 (7.1%) 152 (3.7%) 11 (3.5%)
Unknown 2,191 (8.2%) 303 (7.3%) 25 (8.0%)
P-value Reference ,0.001 0.036
Tumor morphology:
Ductal ca 20,524 (76.2%) 3,252 (78%) 263 (84%)
Lobular ca 4,278 (15.9%) 643 (15.4%) 32 (10.2%)
Other 2,139 (7.9%) 274 (6.6%) 18 (5.8%)
P-value Reference 0?005 0.002
Treatment selection:
Any surgery; n (%) 24,908 (92.5%) 3,989 (95.7%) 297 (94.9%)
P-value Reference 0.003 NS
Any radiation therapy; n (%) 14,474 (53.7%) 2,291 (55.0%) 170 (54.3%)
Chemotherapy 6,367 (23.6%) 628 (15.1%) 51 (16.3%)
P-value Reference ,0?001 0.012
Hormonal therapy 6,787 (25.2%) 849 (20.4%) 73 (23.3%)
P-value Reference ,0?001 NS
Other therapy 220 (0.8%) 17 (0.4%) 1 (0.3%)
P-value Reference ,0.001 NS
aAny pre-diagnostic or post-diagnostic use.
bAge cutoffs selected to reflect menopausal status of the majority of women at breast cancer diagnosis.
doi:10.1371/journal.pone.0110231.t001
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study cohort, a total of 31,236 cases (31,114 women, 122 men).
Men were excluded from this analysis.
Lipid-lowering drug usage
The status on post-diagnostic statin use was updated prospec-
tively for each year of follow-up since breast cancer diagnosis. The
study participant was categorized as statin user only for the years
with recorded statin purchases, regardless of the amount. Persons
who discontinued prior post-diagnostic statin use were categorized
separately as previous users. Cumulative amount (daily doses),
duration (years) and intensity (doses/year of usage) of post-
diagnostic use were analyzed as prospective time-dependent
continuous variables. At discontinuation the cumulative
amount/duration/intensity of statin use stayed at the level reached
before the usage was stopped.
For prediagnostic use women who were using statins at the year
of diagnosis were categorized as current pre-diagnostic users; those
who had use the drugs before but had stopped prior to the
diagnosis were categorized as previous pre-diagnostic users. Total
cumulative amount, duration and intensity of pre-diagnostic statin
use were calculated since 1995 up to the year of diagnosis.
The amount of usage was standardized for different statins using
the defined daily doses (DDDs) recommended by the World
Health Organization (WHO ATC/DDD index database). [21]
The DDD is the assumed average maintenance dose per day for a
drug used for its main indication in adults. For each year of follow-
up, the total milligram amount for each drug was calculated based
on all purchases reimbursed that year. Yearly mg amount was
divided by the amount corresponding to 1 DDD to obtain the
yearly DDDs. Duration of medication use was calculated as the
cumulative number of years of follow-up with recorded statin
purchases. The total cumulative amount and duration of usage
were obtained by adding together yearly DDDs or years with
statin purchases from the entire follow-up. Intensity of statin use,
i.e. the number of statin doses used per year was calculated by
dividing the yearly number of DDDs with years of usage (DDDs/
year). The study population was stratified into tertiles (post-
diagnostic use) or by median (pre-diagnostic use) of amount,
duration and intensity of usage in order to compare long-term/
high-dose/high-intensity use with short-term/low-dose/low-inten-
sity usage.
Statistical analysis
We used Chi-square test (for categorical variables) and Mann-
Whitney-U test (for continuous variables) to evaluate statistical
significance of the differences in baseline characteristics between
medication users and non-users.
Hazard ratios (HRs) and 95% confidence intervals (CIs) for
breast-cancer specific and all-cause mortality were estimated using
Cox proportional hazards regression, with years since the date of
breast cancer diagnosis as the time-metric. Each cohort member
contributed person-time from the diagnosis until the date of death,
emigration from the country or the end of study period (common
closing date December 31st, 2003), whichever came first.
Tumor stage at diagnosis, morphology and treatment choice
(surgery, radiation therapy, chemotherapy, hormone therapy or
other) were included in the regression model as time-independent
variables. The proportional hazards assumption was checked for
each time-independent variable by including interaction term with
follow-up time into the regression model. In each case, the
Figure 1. Trend in breast cancer mortality by intensity (doses/year) of post-diagnostic statin use. Nationwide cohort of all female breast
cancer patients in Finland during 1995–2003.
doi:10.1371/journal.pone.0110231.g001
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interaction term was not statistically significant, confirming the
assumption.
All HRs are calculated using non-users of cholesterol-lowering
drugs as the reference group. We performed the analyses
separately with an age-adjusted model and a multivariable
adjusted model (adjustment for age, tumor stage, morphology
and treatment selection). Analyses on non-statin cholesterol-
lowering drugs (fibrates and resins) were additionally adjusted for
prior statin usage. We report multivariable-adjusted HRs unless
otherwise stated.
Survival trends by increasing amount, duration or intensity of
statin use were estimated by stratifying the analysis within tertiles
of the amount/duration or deciles of intensity of statin usage. P
values for trends by amount, duration or intensity of statin use
were calculated by including these variables as continuous, time-
dependent variables into Cox regression model.
The analyses were repeated separately for pre-diagnostic (statin
use occurring before the years of diagnosis) and post-diagnostic
statin use.
To address the potential for confounding by indication we
evaluated and controlled for each person’s likelihood of being a
statin user post-diagnosis we calculated propensity score using
logistic regression model with post-diagnostic statin use as the
dependent variable and age, tumor stage, morphology, treatment
selection and pre-diagnostic statin usage as categorical indepen-
dent variables. [22] Of these, pre-diagnostic statin use was the
strongest predictor of post-diagnostic use. The propensity from
each variable was combined to form a total propensity score for
statin use. The analysis was stratified by quartiles of the total
propensity score to ensure comparable distribution of background
characteristics between statin users and non-users.
We evaluated the impact of death due to non-cancer causes on
observed breast cancer mortality with a competing risks regression
as described by Fine and Gray, [23] using the same model
adjustments as for the multivariable adjusted Cox regression
model.
All reported p-values are two-sided. IBM SPSS statistics 20
statistical software (Chicago, Illinois, USA) was used for Cox
regression analyses and STATA version 12 (StataCorp LP,
College Station, Texas, USA) was used for competing risks
regression.
Results
Population characteristics
Of the participants, 4,151 (13.3% of the cohort) had used statins
between 1995 and 2003, while 313 (1% of the cohort) had used
fibrates or resins (Table 1). Of the latter 187 (59.7%) had also used
statins during the study period. The most commonly used statins
were simvastatin (n = 2,031, 48.9% of statin users), atorvastatin
(n = 1,507, 36.3%), and fluvastatin (n = 840, 20.2%).
In total, 1,801 women (5.8% of all) had used statins before
breast cancer diagnosis, while 71 (0.2%) had used fibrates or
Figure 2. Trend in breast cancer mortality by intensity (doses/year) of pre-diagnostic statin use. Nationwide cohort of all female breast
cancer patients in Finland during 1995–2003.
doi:10.1371/journal.pone.0110231.g002
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resins. The usage continued after the diagnosis in 85% and 38% of
previous statin and fibrate/resin users, respectively.
A total of 2,350 new users started statin usage post-diagnosis. Of
these 1,880 (80%) remained adherent users until the end of follow-
up.
During the median follow-up of 3.25 years post-diagnosis 6,011
(19.2%) participants died, of which 3,619 (60.2%) due to breast
cancer. The median follow-up did not differ significantly by
medication usage. Compared to the non-users, medication users
were older and more likely to have localized invasive ductal
carcinoma than lobular carcinoma (Table 1). Surgical treatment
was more common among statin users. Characteristics of fibrate
and resin users were similar to statin users (Table 1).
Breast cancer survival by post-diagnostic statin use
Compared to the non-users, current post-diagnostic statin users
had lowered risk of breast cancer death (multivariable adjusted
HR 0.46, 95% CI 0.38–.055), whereas women who had stopped
statin use post-diagnosis (previous users) had elevated risk
compared to non-users (HR 1.67, 95% CI 1.22–2.27). The risk
decrease among current statin users was observed both in localized
and metastatic cases at diagnosis (Table 2).
In stratified analyses the risk decrease strengthened by
increasing cumulative amount and intensity of post-diagnostic
use, especially among participants with metastatic tumors
(Table 2). No statistically significant trends were observed by
increasing amount and duration of post-diagnostic statin use, but a
significant decreasing trend in breast cancer mortality was
observed with increasing intensity of statin usage (p for trend,
0.001) (Figure 1).
Table 4. Risk of breast cancer death by current pre-diagnostic and post-diagnostic statin use within a cohort of all breast cancer
patients diagnosed in Finland during 1995–2003.
Risk of breast cancer death
Pre-diagnostic statin use Post-diagnostic statin use
HR (95% CI) multivar. adjusted
a HR (95% CI) multivar. adjusted
a
Propensity scoreb:
1st quartile 1.23 (0.66–2.29) 0.42 (0.24–0.74)
2nd quartile 0.82 (0.39–1.73) 0.26 (0.12–0.59)
3rd quartile 0.79 (0.43–1.48) 0.51 (0.33–0.78)
4th quartile 0.84 (0.65–1.10) 0.50 (0.38–0.66)
Age
.= 55 years 0.73 (0.39–1.36) 0.44 (0.26–0.75)
,55 years 0.59 (0.47–0.72) 0.39 (0.31–0.48)
Pre-diagnostic statin use
Yes - 0.45 (0.27–0.75)
No Initial treatment choice - 0.31 (0.22–0.44)
Surgery:
Yes 0.63 (0.48–0.83) 0.39 (0.30–0.50)
No 0.63 (0.37–1.07) 0.49 (0.26–0.88)
Radiation therapy:
Yes 0.68 (0.46–1.00) 0.30 (0.20–0.44)
No 0.45 (0.32–0.63) 0.38 (0.28–0.52)
Chemotherapy:
Yes 0.75 (0.50–1.13) 0.45 (0.29–0.69)
No 0.48 (0.36–0.64) 0.38 (0.30–0.49)
Hormone therapy:
Yes 0.70 (0.47–1.05) 0.53 (0.36–0.79)
No 0.47 (0.35–0.62) 0.33 (0.25–0.43)
Combination treatments:
Surgery and radiation therapy 0.71 (0.54–0.93) 0.37 (0.28–0.49)
Surgery and chemotherapy 1.06 (0.76–1.47) 0.45 (0.31–0.64)
Surgery and hormone therapy 0.77 (0.54–1.09) 0.47 (0.33–0.67)
Radiation and chemotherapy 1.11 (0.78–1.57) 0.45 (0.31–0.66)
Radiation and hormone therapy 0.89 (0.63–1.28) 0.54 (0.37–0.78)
Analysis stratified by propensity for post-diagnostic statin use, population characteristics at baseline and primary treatment selection.
aCalculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.
bPropensity for post-diagnostic statin usage as a function of age, tumor stage and morphology, initial treatment choice and pre-diagnostic statin use.
doi:10.1371/journal.pone.0110231.t004
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Pre-diagnostic statin use and survival
Women who had used statins pre-diagnosis and were still users
at the year of breast cancer diagnosis had lowered risk of breast
cancer death compared to non-users (HR 0.54, 95% CI 0.44–
0.67), whereas previous pre-diagnostic use (usage stopped before
the year of diagnosis) was not associated with the risk (HR 0.70,
95% CI 0.46–1.07) (Table 3). A significant decreasing trend by
increasing cumulative amount, duration and intensity of pre-
diagnostic statin was observed (Table 3). This was observed both
for localized and metastatic cases at diagnosis. Unlike for post-
Table 5. Overall risk of death among post-diagnostic and pre-diagnostic statin users compared to non-users.
Overall risk of death
Localized cases at diagnosis Metastatic cases at diagnosis
n of cases n of deaths
HR (95% CI) multivar.
adjusted*
n of cases n of deaths
HR (95% CI) multivar.
adjusted*
Post-diagnostic
statin use
23,098/3,455
(non-users/users)
3,779/232
(non-users/users)
1,930/130
(non-users/users)
1,154/38
(non-users/users)
None Ref Ref
Current 0.39 (0.33–0.46) 0.55 (0.39–0.78)
Previous 1.27 (0.98–1.65) 1.16 (0.48–2.82)
Amount of statin use
1st tertile
(10–322 DDD)
1,138 91 0.56 (0.45–0.69) 60 26 0.73 (0.49–1.08)
2nd tertile
(333–800 DDD)
1,152 73 0.48 (0.38–0.61) 49 9 0.41 (0.21–0.80)
3rd tertile
(801 DDD or more)
1,165 44 0.37 (0.27–0.50) 21 3 0.38 (0.09–1.53)
Duration of
statin use
1 year 1,126 78 0.55 (0.44–0.69) 80 26 0.63 (0.43–0.93)
2–3 years 1,382 88 0.46 (0.37–0.57) 39 10 0.50 (0.26–0.96)
4 years or
longer
947 42 0.41 (0.30–0.57) 11 2 0.58 (0.14–2.36)
Intensity of statin use (DDDs/year)
14–183 1,143 102 0.59 (0.47–0.73) 56 23 0.79 (0.51–1.22)
184–300 1,208 66 0.41 (0.32–0.53) 35 12 0.42 (0.21–0.84)
301 or more 1,104 40 0.45 (0.34–0.58) 39 3 0.47 (0.23–0.94)
Pre-diagnostic
statin use
n of cases n of deaths HR (95% CI)
multivar. adjusted*
n of cases n of deaths HR (95% CI)
multivar. adjusted*
None 24,599 3,841 Ref 1,932 1,144 Ref
Current 1,652 120 0.58 (0.49–0.70) 106 36 0.66 (0.47–0.92)
Previous 302 26 0.80 (0.54–1.17) 22 12 1.18 (0.67–2.10)
Amount of use
1–495 DDD 978 94 0.69 (0.56–0.84) 61 29 0.91 (0.63–1.31)
496 DDD or more 976 52 0.51 (0.39–0.68) 67 19 0.58 (0.37–0.92)
Years of use
1–3 years 1,286 114 0.66 (0.55–0.80) 85 35 0.84 (0.60–1.17)
4 years
or longer
668 32 0.49 (0.34–0.69) 43 13 0.57 (0.33–0.99)
Intensity
of use
195
DDDs/year or less
981 89 0.68 (0.55–0.83) 69 32 0.82 (0.57–1.17)
Over 196
DDDs/years
973 57 0.54 (0.41–0.70) 59 16 0.63 (0.38–1.03)
Cohort of all breast cancer patients diagnosed in Finland during 1995–2003.
*Calculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.
DDD=Defined Daily Dose.
doi:10.1371/journal.pone.0110231.t005
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diagnostic usage, no significant risk decrease was observed for low-
intensity pre-diagnostic use, but only for high-intensity usage
(Figure 2).
Stratified analyses
Stratification by quartiles of propensity score ensured similar
propensity for post-diagnostic statin use between users and non-
users in the first two quartiles (standardized mean difference 0.09
and 0.05, respectively). In the third and fourth quartiles the
propensity score was not perfectly balanced between statin users
and non-users (standardized mean difference 0.117 and 1.22,
respectively), mainly because post-diagnostic statin users in these
quartiles were mostly also pre-diagnostic users, which was the
strongest predictor of post-diagnostic use causing high propensity
scores.
For post-diagnostic statin use the risk of breast cancer death was
similarly decreased in all quartiles of propensity score (Table 4).
Further, stratification by pre-diagnostic statin use, age group or
treatment selection did not clearly modify the risk decrease
(Table 4).
The risk estimates for pre-diagnostic statin use were mostly non-
significantly decreased in stratified analysis, with no clear effect
modification (Table 4).
All-cause mortality
Similar to breast cancer-specific mortality also all-cause
mortality was lowered in current, but not previous pre- and
post-diagnostic statin users. Again, the association was clearer with
continued and more intensive usage (Table 5).
Survival by statin type
All three most commonly used statins were associated with
decreased risk of breast cancer death in participants with localized
tumors both when used pre- or post-diagnosis (Table 6). Also post-
diagnostic use of hydrophilic pravastatin was linked with lowered
risk, whereas pre-diagnostic use was not. Among participants with
metastatic disease at diagnosis, only simvastatin users had
decreased risk of breast cancer death. However, the lack of
significant associations for other statins may be due to small
numbers. (Table 6).
Sensitivity analyses
Fibrates and bile-acid binding resins were not associated with
all-cause mortality in patients with localized cancer (HR 1.06,
95% CI 0.47–2.37) but were linked to higher mortality in patients
with metastatic disease (HR 1.85, 95% CI 1.07–3.20). The
number of fibrate/resin users was too low to estimate breast
cancer-specific mortality.
Decreased risk of breast cancer death among statin users was
not explained by increased risk of death from other causes; the
mortality decrease was observed also in multivariable adjusted
competing risks regression, with non-cancer deaths as a competing
cause of death (HR 0.27, 95% CI 0.22–0.32).
Women dying of breast cancer may have been more likely to
drop statin use during the final months of life. However, the
inverse association between post-diagnostic statin use and breast
cancer mortality remained after exclusion of changes to statin
usage status during the final year of follow-up (HR 0.33, 95% CI
0.24–0.45 and 0.63, 95% CI 0.39–1.02 for localized and
metastatic cancer, respectively).
Table 7. Risk of breast cancer death by amount, years and intensity of post-diagnostic statin use as compared to non-users.
Risk of breast cancer death
Statin use n of cases n of deaths HR (95% CI) multivar. adjusted
a
Never 26,963/1,908
(users/non-users)
3,439/47
(users/non-users)
Reference
Current 0.31 (0.22–0.44)
Former 1.04 (0.60–1.80)
Risk of breast cancer death by amount of post-Dx statin use
Amount of statin use
1st tertile (10–322 DDD) 755 25 0.41 (0.27–0.61)
2nd tertile (333–800 DDD) 600 13 0.32 (0.18–0.56)
3rd tertile (801 DDD or more) 553 9 0.45 (0.23–0.86)
Risk of breast cancer death by years of post-Dx statin use
Years of statin use
1 year 687 23 0.41 (0.27–0.62)
2–3 years 760 16 0.35 (0.22–0.58)
4 years or longer 461 8 0.41 (0.19–0.86)
Risk of breast cancer death by intensity of post-Dx statin use
Intensity of statin use
14–183 DDDs/year 773 25 0.44 (0.29–0.67)
184–300 DDDs/year 632 13 0.28 (0.15–0.52)
301 DDDs/year or more 503 9 0.42 (0.24–0.74)
Statin users limited to new post-diagnostic users only.
aCalculated with Cox regression model adjusted for age, tumor stage and morphology and treatment selection.
DDD=Defined Daily Dose.
doi:10.1371/journal.pone.0110231.t007
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The impact of prevalent user bias was evaluated by limiting the
analysis to new post-diagnostic statin users only. The risk decrease
was observed also in this group of statin users, but with no dose-
dependence by amount, duration or intensity of use (Table 7).
However, after limiting the analysis to adherent new post-
diagnostic users, a significant decreasing trend in breast cancer
deaths was observed by years and intensity (p for trend= 0.018
and 0.006, respectively) but not by cumulative amount of post-
diagnostic use.
Hazard of breast cancer death remained decreased among post-
diagnostic statin users when the minimum follow-up was set to be
5 or 7 years (HR 0.23, 95% CI 0.13–0.39 and HR 0.42, 95% CI
0.19–0.95, respectively), suggesting that the risk decrease remains
even in the long-term.
Discussion
We have demonstrated lowered risk of breast cancer death
among statin users in a nationwide cohort of all breast cancer
patients diagnosed in Finland during a period of nine years. The
risk decrease was observed for both localized and metastatic
disease at diagnosis, and both for pre-diagnostic and post-
diagnostic statin use. The association was dose-dependent
especially for pre-diagnostic usage. The risk decrease was not
modified by differences in age, tumor characteristics and treatment
selection between statin users and non-users. This association was
not observed for other types of cholesterol-lowering drugs despite
similar age, tumor and treatment characteristics, and was not
explained by competing causes of death or decreased likelihood of
statin usage at the end of life.
Our results could have been affected by healthy user bias,
created by a tendency of healthier patients’ greater likelihood to
initiate and adhere to statin therapy, leading to decreased
likelihood of outcomes not causally related to statin use, such as
risk of accidents. [24] In case of cancer mortality this would mean
that healthier cancer patients are more likely to initiate statin use,
while less healthier would be less likely to initiate usage and more
likely to stop previous use. Indeed, when analyzing current and
previous post-diagnostic statin use the risk of death was elevated in
women who had stopped previous statin use after the diagnosis.
Thus post-diagnostic use was likely affected by the healthy adherer
bias, i.e. by increased likelihood of fatally ill cancer patients to stop
statin usage and lowered likelihood to start it which makes survival
in statin users seem better than it really is. This is likely the reason
for absence of clear dose-dependence for post-diagnostic statin use,
the risk decrease being observed already at short-term and low-
dose usage as well as with longer-term usage. However, for pre-
diagnostic statin use the risk association was dependent on the
amount, duration and intensity as well as timing of statin use, as
would be expected in a causal association. As breast cancer could
not have affected the patients’ decisions on statin use before the
diagnosis, the healthy adherer effect is unlikely to affect pre-
diagnostic statin use.
A major strength of our study is the nationwide coverage of all
incident breast cancer patients in Finland from 1995–2003,
reducing the possibility of selection bias and allowing us several
unique opportunities: the ability to evaluate the association by
stage, perform analysis by statin type and compare mortality by
the type of cholesterol-lowering drug being used. Another
important strength is our detailed knowledge on timing, dosage
and duration of statin use, allowing incorporation of the time
varying nature of the medication use into analysis and reliable
estimation of dose-dependence. Although our median follow-up
was only 3.25 years post-diagnosis, the results were unchanged in
sensitivity analysis with minimum follow-up set to seven years,
showing that the mortality decrease remains also in the long-term.
Previous laboratory studies have demonstrated that statins
inhibit breast cancer cell growth in vitro, [2–4] providing
biological plausibility to statins’ inhibitory effect on breast cancer
progression. A pre-surgical clinical trial supported this by
demonstrating decreased proliferation activity and increased
apoptosis in high-grade, but not low-grade breast cancer tissue
among patients randomized to receive either high-dose fluvastatin
(80 mg/day) or low-dose fluvastatin (20 mg/day) for 3–6 weeks
before mastectomy. [25] Another presurgical clinical study
reported antiproliferative effect of atorvastatin on invasive breast
cancer when given for two weeks before mastectomy at 80 mg/
day dose. [26] This effect was observed only in tumors expressing
HMGCR at baseline, suggesting that statins target this enzyme in
breast cancer tissue. Another possible mechanism for the anti-
cancer action is decreased estrone sulfate level. [27] Our results
are consistent with previous studies reporting lowered overall
cancer mortality in statin users. [9–13,17] Similar to our study,
one study estimating effects of pre-diagnostic statin use reported
lowered breast cancer mortality in a sub-analysis. [13] Another
cohort study found no association between breast cancer mortality
and self-reported lipid-lowering drug usage at diagnosis. [17] The
results of this study could have been biased towards the null as it
did not take into account post-diagnostic statin use. Our study is
the largest study to examine this question with ability to analyze
statin usage occurring both before and after breast cancer
diagnosis.
Cardiovascular disease prevention trials have shown lowered
overall mortality in statin users compared to the non-users. [28] A
recent meta-analysis of such trials concluded that lowering LDL
with statins did not affect cancer risk or mortality during median
follow-up of 4.8 years. [29] However, due to the inclusion criteria
of included trials most participants did not have cancer at the
baseline. Because 5-year disease-specific survival in breast cancer is
up to 89% [30] the risk of dying of breast cancer within the next
4.8 years in a cohort of cancer-free people at baseline is very low.
Therefore the present clinical trials testing statins for prevention of
cardiovascular outcomes have too short follow-up to study breast
cancer mortality leading to underpowered analysis. In the meta-
analysis 41 breast cancer deaths occurred among 85,683 women
included in the trials, which translates to 0.96 deaths/10,000
women/year, which is lower than the average number of breast
cancer deaths in the general population: 2.26 deaths/10,000
women/year. [30] This demonstrates how selected the partici-
pants of the cardiovascular disease prevention trials are in this
regard, and the value of population-based studies such as ours.
The final proof of statins’ anticancer effects or the lack of such
needs to come from clinical trials recruiting specifically cancer
patients.
The significant mortality decrease in our study was evident
already after short-term post-diagnostic statin use. Spontaneous
decrease in serum cholesterol has been reported for years before
cancer death. [31] Thus lower mortality observed already at the
initiation of usage may have been because people dying of breast
cancer had less hypercholesterolemia, i.e. indication for statin use.
Nevertheless, statins may also have a direct short-term effect on
cancer progression as recent clinical trials have demonstrated
decreased breast cancer proliferation after just weeks of statin
usage. [25,26] Whatever the reason for the initial mortality benefit
between statin users and non-users, the dose-dependent decrease
in breast cancer mortality by increasing intensity of usage supports
a causal effect.
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When analyzed separately the risk decrease was not clearly
modified by statin potency, as similar risk decrease was observed
for high-potent atorvastatin as for other statins. Also hydrophilic
pravastatin was associated with a similar decrease as lipophilic
statins. This suggests that statins’ anticancer effects in vivo are due
to a systemic effect common to all statins, such as cholesterol-
lowering.
Our study has several limitations. We could not evaluate
whether statins’ effect on mortality was modified by tumor
hormone receptor status as this information was unavailable.
Neither did we have information on breast cancer screening
history, which could have been more common among statin users,
[32] possibly causing lead-time bias by earlier breast cancer
diagnoses. However, the observed risk decrease even among
metastatic cases at diagnosis indicates that lead-time bias may not
affect our results to any great degree. Our data lacked information
on life-style factors, such as obesity, and usage of medications apart
from cholesterol-lowering drugs. It could be assumed that fibrate
and resin users are in general similar to statin users regarding these
unmeasured factors, yet lower mortality was observed only in
statin users. Thus lifestyle factors may not have a great influence
on our results. Finally, we did not have information on serum
cholesterol levels in our cohort and could not assess the indications
for statin usage.
In conclusion, statin users had lower risk of breast cancer death
compared to non-users in a nationwide cohort of Finnish breast
cancer patients. Combined with previous evidence from in vitro
[2–4], epidemiological [14–17] and clinical studies [25,26] our
study suggests that, apart from cardiovascular benefits, statins may
have beneficial effect against breast cancer progression. However,
because uncertainty remains due to biases related to differing
likelihood for statin use in different patient groups our results need
to be confirmed in a randomized clinical trial before statins can be
recommended for breast cancer treatment.
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